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Abstract
Aims The objective of this study was to examine baseline frailty status (including cognitive deficits) and important clinical 
outcomes, to inform shared decision-making in older adults receiving transcatheter aortic valve implantation (TAVI).
Methods and results We conducted a prospective, observational study of 82 TAVI patients, recruited 2013 to 2015, with 
2-year follow-up. Mean age was 83 years (standard deviation (SD) 4.7). Eighteen percent of the patients were frail, as assessed 
with an 8-item frailty scale. Fifteen patients (18%) had a Mini-Mental Status Examination (MMSE) score below 24 points 
at baseline, indicating cognitive impairment or dementia and five patients had an MMSE below 20 points. Mean New York 
Heart Association (NYHA) class at baseline and 6 months was 2.5 (SD 0.6) and 1.4 (SD 0.6), (p < 0.001). There was no 
change in mean Nottingham Extended Activities of Daily Living (NEADL) scale between baseline and 6 months, 54.2 (SD 
11.5) and 54.5 (SD 10.3) points, respectively, mean difference 0.3 (p = 0.7). At 2 years, six patients (7%) had died, four (5%, 
n = 79) lived in a nursing home, four (5%) suffered from disabling stroke, and six (7%) contracted infective endocarditis.
Conclusions TAVI patients had improvement in symptoms and maintenance of activity of daily living at 6 months. They had 
low mortality and most patients lived in their own home 2 years after TAVI. Complications like death, stroke, and endocar-
ditis occurred. Some patients had cognitive impairment before the procedure which might influence decision-making. Our 
findings may be used to develop pre-TAVI decision aids.
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Introduction
Transcatheter aortic valve implantation (TAVI) is an estab-
lished treatment for severe and symptomatic aortic stenosis 
in patients not eligible for open heart surgery, and it improves 
symptoms and increase life expectancy [1, 2]. While indi-
cation for TAVI has expanded to also include younger and 
lower risk groups, the majority of TAVI patients are older 
and have significant comorbidity and frailty that contraindi-
cated surgery. The Valve Academic Research Consortium-2 
(VARC 2) consensus document recommends evaluation of 
independence in activity of daily living before the procedure 
as risk stratification [3]. However, few studies have focused 
on independence in activity of daily living as an outcome 
measure [4, 5].
Among older adults who are seriously ill, death might not 
be feared as the worse outcome. For many, reduced quality 
of life and functional or cognitive impairment [6, 7], are 
relatively greater concerns. Dementia is highly prevalent in 
older adults [8] and is the leading cause of dependency in 
older age [9]. Shared decision-making is the favoured model 
for health care decisions, enhancing treatment choices to 
reflect patients’ values and preferences [10]. However, the 
context of cognitive impairment or dementia makes it more 
difficult for TAVI candidates to participate in the decision-
making process [11].
Thus, the aim of this study was to examine baseline frailty 
status including cognition and outcomes important to deci-
sion-making prior to TAVI.
Methods
Study design
This is a single-centre prospective, observational cohort 
study of 82 elective TAVI patients, with 2-year follow-up. 
Ninety-four patients were eligible for inclusion, five refused 
to participate and seven were not included due to logisti-
cal reasons. The patients were recruited consecutively from 
2013 to 2015.
Participants
Patients ≥ 70 years with symptomatic and severe aortic ste-
nosis accepted for TAVI at Haukeland University Hospital in 
Western Norway were included. The hospital has a tertiary 
function for TAVI and serves a population of 1.1 million 
inhabitants. Severe aortic stenosis was defined by echocar-
diography according to the European Society of cardiology 
(ESC) guidelines [1]. Before accepting patients for TAVI, 
a heart team including interventional cardiologists, cardiac 
surgeons and imaging specialists, had declined them for sur-
gical aortic valve replacement due to high risk. At the time 
of the study, there was no screening for frailty preceding the 
intervention, and the frailty score of the study patients was 
not known to the treatment team. The number of patients 
selected for conservative treatment is not known but sus-
pected to be small. Nursing home patients and patients with 
severe dementia are rarely referred for valve intervention in 
Norway. Exclusion criteria were inability to understand or 
speak Norwegian.
Procedural characteristics
TAVI was delivered by different routes, seventy five (92%) 
trans-femoral, five trans-subclavian and two with direct aor-
tic access. Two different valves were used, the Medtronic 
Core Valve in 52 (63%) and Boston Scientific LOTUS Valve 
in 30 (37%) patients.
Measurements
Baseline
Mini-Mental Status Examination (MMSE) assesses cogni-
tion as a scale that ranges from 0 to 30, with higher scores 
indicating better cognition [12]. The cut-off for normal 
cognitive function is usually set at 24, with a sensitivity 
of 0.85 and a specificity of 0.90 for identifying anyone 
with dementia [13].
The research team developed an 8-item frailty scale 
[14]. The total score is calculated by adding different 
domain scores: cognition (MMSE ≥ 27 = 0 points, MMSE 
20–26 = 1 point, MMSE ≤ 19 = 2 points), instrumental 
activity of daily living (NEADL ≤ 43 = 1 point), nutrition 
(BMI < 20.5 = 1 point), modified SOF (low energy = 1 
point, weight loss (reported, not measured weight loss; 
therefore, modified) = 1 point, chair stand, not able = 1 
point) [15], Charlson Comorbidity Index (≥ 3 = 1 point) 
[16], and psychological factors (HADS ≥ 15 = 1 point) 
[17]. The score range from 0 to 9, were 9 represents 
the frailest patients. Patients were classified frail if they 
scored ≥ 4 points. This cut-off had a specificity of 80% and 
sensitivity of 60% at predicting 2-year mortality for this 
population. In a receiver operating curve, the area under 
the curve was 0.81 (95% confidence interval 0.71–0.90) 
[14].
Aging Clinical and Experimental Research 
1 3
Baseline and 6 months:
Nottingham Extended Activity of Daily living scale 
(NEADL) is a scale originally developed to assess activi-
ties of daily living (ADL) for stroke patients discharged to 
home, yet frequently used in non-stroke populations [18, 
19]. The scale measures extended activities of daily living 
using a 22-item questionnaire, evaluating four different 
sections: mobility, kitchen, domestic and leisure. Patients 
are asked whether they perform the different activities, and 
the response categories are 0 = not at all, 1 = with help, 
2 = on my own with difficulty, 3 = on my own. The dif-
ferent scores sums into a total score of 0 to 66 points, 
with higher scores indicating greater independence. A 
score ≤ 43 indicates dependence [19]. One study of stroke 
patients reported a valid and reliable change if the NEADL 
improved or deteriorated by 4.9 points or more, and clini-
cally important if the mean change score was in the range 
from 2.4 to 6.1 points after treatment [20].
The New York Heart Association (NYHA) classification 
describes patients’ symptoms of heart failure [21] and has 
been applied to TAVI patients [3]. NYHA class I repre-
sents no symptoms of heart failure and no limitation of 
physical activity, while NYHA class IV represents symp-
toms of heart failure at rest. Despite limitations it’s widely 
used both in research and clinical practice.
Follow‑up measurements
Baseline NEADL and NYHA were assessed and then 
repeated at 6 months. Due to some patients living far from 
the hospital, we performed telephone interviews at 6 months, 
and MMSE and frailty testing were, therefore, not con-
ducted. For the first 2 years, we recorded composite end-
points as recommended by the Valve Academic Research 
Consortium-2 (VARC-2) consensus document. We collected 
data of admission to long-term nursing homes for the first 
2 years.
Statistical analyses
We present the data as means and standard deviations (SD), 
counts and percentages. Changes from baseline to 6 months 
are analysed using paired t-tests. There were little missing 
data so we have used complete case analysis and report the 
number of observations each analysis is based on. Statisti-
cal analysis was carried out in IBM SPSS Statistic 24 and R 





We examined 82 patients with severe and symptomatic aor-
tic stenosis, 39 (48%) women. Mean age was 83 years (SD 
4.7), two patients were over 90 years, the oldest 95 years old, 
and there were six patients under 75 years. Most patients 
(62%) lived with their spouse. A majority (55%) had only 
primary school, while 20% had a university degree.
Geriatric characteristics
Fifteen patients (18%) had an MMSE score < 24, suggest-
ing they were cognitively impaired. One fifth of the patients 
had a low NEADL score (≤ 43), implying dependence in at 
least one instrumental activity of daily living. As expected, 
NEADL and MMSE was correlated (Spearman’s rho = 0.47, 
p < 0.001). Eleven patients had a low BMI, however, 27 
(33%) reported weight loss last year. Charlson comorbid-
ity index was ≥ 3 in 36 (44%) of the patients, demonstrat-
ing a high burden of comorbidity. Six (7%) patients had a 
score ≥ 15 on the Hospital Anxiety and Depression Scale; 
i.e., few patients had severe anxiety or depression. For 80 
patients, baseline 8-item frailty scale was calculated, and 14 
patients (18%) were defined as frail.
Cardiovascular characteristics
Logistic EuroSCORE [23] was below 10 (predicting low 
surgical risk) in 20 (24%) and over 20 (high surgical risk) in 
19 (23%) of the patients. Almost half (48%) of the patients 
had NYHA ≥ 3 at baseline, indicating a significant bur-
den of symptoms. Few patients (11%) had a pacemaker 
before TAVI, and 26 (32%) had atrial fibrillation at baseline 
(Table 1).
Follow‑up
One patients was lost to follow-up at the telephone inter-
view and three had died. For three patients, information was 
missing on whether they lived at home or in nursing home 
at 2-year follow-up. VARC 2 composite endpoint is pre-
sented in Table 2, and endocarditis is separately presented 
in Table 3 with complementary data.
Mortality and morbidity
Two patients (2%) died early (< 30 days), and one had a 
disabling stroke. At 1 year, four patients (5%) had died and 
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4 (5%) had a disabling stroke. After 2 years, 6 (7%) patients 
had died, five of cardiovascular and one of non-cardiovascu-
lar cause. Four patients lived in nursing homes. There were 
no new disabling stroke from one to 2 years. Six patients 
(7%) had endocarditis during the first 2 years. Thirty-two 
patients (39%) got a new pacemaker perioperative (during 
the hospital stay).
Patient‑reported outcome measures at 6 months
NEADL
The NEADL score was available in 78 patients at 6 months. 
All patients were reached in person except for one, where the 
spouse provided information. For one patient, only NEADL 
at 6 months was available. There was no change in mean 
NEADL (n = 77) at baseline and 6 months with 54.2 (SD 
11.5) and 54.5 (SD 10.3), respectively, mean difference 
0.3 (p = 0.7). Even so, 13 patients (17%) improved 5 points 
or more at the NEADL from baseline to 6 months, and 14 
patients (18%) deteriorated 5 points or more. We did not 
find an association between frailty status and deterioration in 
NEADL score. For example, the proportion of patients who 
deteriorated in NEADL score was similar in the frail and 
the non-frail group (42% and 55%, respectively, p = 0.53, 
Fisher’s exact test).
NYHA class
After 6 months, the majority was in NYHA I (68%), about 
a quarter were in NYHA II (27%) and a few in NYHA III 
(5%). No patients were in NYHA IV. Mean NYHA (n = 78) 
at baseline and 6 months was 2.5 (SD 0.6) and 1.4 (SD 0.6), 
respectively, a significant improvement (p < 0.001). Four 
patients had missing NYHA class at 6 months (three dead, 
one lost to follow-up) (Fig. 1).
Table 1  Patient baseline characteristics (n = 82)
The total score is calculated by adding the different domain scores
MMSE mini-mental status examination, NEADL Nottingham 
extended activities of daily living scale, BMI body mass index, SOF 
study of osteoporotic fractures, HADS hospital anxiety and depres-
sion scale
Mean or count SD or (percent)
Characteristics
 Age, years 83 4.7
 Women 39 (48)
 Living alone 29 (35)
 Education
  Primary School 45 (55)





  MMSE ≥24 67 (82)
  MMSE 20–23 10 (12)
  MMSE <20 5 (6)
 Activities of daily living
  NEADL ≤43 15/80 (19)
 Nutrition
  BMI 24.8 3.6
  BMI <20.5 11 (13)
 mSOF
  Weight  lossa 27 (33)
  Low energy 32 (39)
  Unable to chair stand 10 (12)
 Comorbidity
  Charlson Comorbidity Index 2.6 1.4
  Charlson Comorbidity Index ≥3 36 (44)
 Psychological factors
  HADS ≥15 6/81 (7)
 Frailtyb 14/80 (18)
Cardiovascular characteristics
 Logistic EuroSCORE 15 7.9
 Aortic Valve Area Index,  cm2/m2 0.4 0.12
 Mean Aortic Valve gradient, 
mmHg
50 15
 Left ventricular ejection fraction 57 12
 NYHA ≥III 39 (48)
 Previous myocardial infarction 15 (18)
 CABG 15 (18)
 Permanent pacemaker 9 (11)
 Atrial fibrillation 26 (32)
 Pulmonary hypertension 27 (33)
 Cerebral Vascular Disease 12 (15)
Comorbidity
 COPD 19 (23)
 Kidney failure; creatinine >177 
µmol/Lc
4 (5)
a Modified from the original SOF, with patient-reported weight loss 
past year, not measured as in the original index (mSOF modified 
SOF)
b 8-item geriatric assessment frailty scale. Missing information to 
calculate the scale in two patients, NYHA, New York Heart Asso-
ciation functional classification of heart failure, range from I to IV, 
most severe symptoms at IV. CABG coronary artery bypass grafting, 
COPD chronic obstructive pulmonary disease
c As reported in the PARTNER study [2]; Creatinine > 2 mg/dl (177 
µmol/L)
Table 1  (continued)
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Discussion
This prospective observational study of 82 patients docu-
ments symptom improvement and maintenance of activities 
of daily living 6 months after TAVI. They had low mortal-
ity and most patients lived in their own home 2 years after 
TAVI. At baseline, 18% had an MMSE score, indicating 
cognitive impairment or dementia. We found a higher fre-
quency of endocarditis than expected. According to the basic 
principles of shared decisions-making, balanced information 
regarding risks and benefits, and exploring patients’ values 
and goals are important. Physicians should be aware that 
patients’ cognitive impairment or dementia might affect the 
ability to participate in the decision-making process and give 
an informed consent.
Mortality at one (5%) and 2 years (7%) after TAVI was 
low in this cohort, where mean age is over 80 years and there 
is a substantial burden of comorbidity and frailty. We found 
a substantial improvement in NYHA class from baseline 
to 6 months. Based on the improvement of symptoms we 
expected to find an improvement in NEADL. However, we 
found no change in mean NEADL. There was a variation on 
an individual level. Some patients improved their independ-
ence and others deteriorated, although for most patients, the 
Table 2  Composite endpoints according to VARC  2a criteria
SAVR Surgical aortic valve replacement, TAVI transcatheter aortic valve implantation, NYHA New York Heart Association
a The Valve Academic Research Consortium (VARC)-2 consensus document (see references)
b Immediate or consequent death ≤ 72 h post-procedure
c No prosthesis-patient mismatch. Mean aortic valve gradient < 20 mmHg or peak velocity < 3 m/s
d After TAVI procedure at index hospitalization
e Assessment of stroke at index. All strokes verified by CT/MRI
f Evaluation of acute kidney injury is based on serum creatinine, we miss data on urine output
g NYHA at 6 months
h Four patients had new paravalvular leak or vegetation on the aortic valve
Total (n = 82) Percent
Device success
Absence of immediate procedural  mortalityb 82 100
Correct positioning 81 99
Intended performance of the prosthetic heart  valvec 81 99
No moderate or severe prosthetic valve  regurgitationd 78 95
Early safety (at 30 days)
All-cause mortality 2 2
All stroke(disabling or non-disabling) in  hospitale 1 1
Life-threatening or disabling bleeding 4 5
Acute kidney injury-stage 2 or  3f 2 2
Coronary artery obstruction requiring intervention 1 1
Major vascular complication 5 6
Valve-related dysfunction requiring intervention 1 1
Clinical efficacy (30 days–2 years)
All-cause mortality 4 5
All stroke(disabling or non-disabling) 5 6
Requiring hospitalizations for valve-related symptoms or worsening congestive heart failure 13 16
NYHA class III or  IVg 4 5
Time-related valve safety
Structural valve deterioration
 Valve-related dysfunction (mean aortic valve gradient ≥20 mmHg) and/ or moderate or severe prosthetic 
valve  regurgitationh
15/81 19
 Requiring repeat procedure (TAVI or SAVR) 1 1
Prosthetic valve  endocarditisf 6 7
Trombo-embolic events (eg stroke) 6 7
VARC bleeding (life threatening/disabling bleeding or major bleeding), unless clearly unrelated to valve 
therapy (e.g. trauma)
14 17
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change in NEADL was minor. Other factors, like frailty and 
dementia, probably have more impact on the level of inde-
pendence than the aortic stenosis per se [4], and 6 months 
follow-up is probably too short to establish deterioration due 
to other causes. There was no difference between the frail 
and robust patients regarding change in NEADL from base-
line to 6 months.
At baseline, 15 patients had an MMSE below 24, indi-
cating possible cognitive impairment or dementia [13]. 
Five patients had an MMSE less than 20, which increases 
the probability of incapacity, and likely reduces their 
power of judgement during the decision-making processes 
before TAVI [11]. Several studies have suggested that a 
low MMSE score at baseline predicts poor outcomes after 
TAVI [4, 24]. However, there are also studies demonstrat-
ing cognitive improvement after TAVI when impairment 
is caused by the aortic stenosis itself [25]. For patients 
with established dementia, surviving to end stage dementia 
might not be what the patient would choose autonomously. 
These are difficult issues to discuss with patients with 
dementia and their families, both due to patients’ anosog-
nosia (a physiological damage to the brain, where patients 
have no awareness of their disease) [26], and also health 
care professionals’ fear of patients losing hope when 
focusing on the deterioration and increased dependence 
expected after a diagnosis of dementia [27]. It is impor-
tant to point out that an MMSE < 24 is not diagnostic of 
dementia, and sensitivity and specificity for MMSE cut-
offs in a TAVI population, might be different than in the 
general population. Suspicion of dementia should, there-
fore, lead to further investigations.
Table 3  Infective endocarditis first 2 years after TAVI
TTE transthoracic echocardiography, TEE trans-oesophageal echocardiography, PVL para valvular leak, PM pacemaker, CRT-P/D coronary 
resynchronisation therapy with cardiac defibrillator (D) or pacemaker (P)
a y years, M male, F female
b All meet criteria for definite infective endocarditis (IE) except the last patient who has a possible IE. All patients had trans-femoral access for 
TAVI
c Died five months after diagnosed with IE
d Died one month after diagnosed with IE








Dukes  criteriab Outcome two 
year
TTE and TEE Pacemaker device
Lotus 27 mm 86 y, F 49 Stafylococcus 
aureus
1 Major + 3 
minor
Dead c No vegetation or 
PVL
PM, 1 day after 
TAVI
Core valve 31 
mm
77 y, M 190 Streptococcus 
salvarius
2 Major + 2 
minor
Alive Aortic valve 
vegetation
CRT-D , 3 months 
before TAVI
Core valve 31 
mm
80 y, M 380 Enterococcus 
faecalis
1 Major + 3 
minor
Alive New aortic PVL CRT-P, 2 months 
after TAVI
Core valve 29 
mm
79 y, M 407 Streptococcus 
sanguinis
1 Major + 3 
minor
Alive New aortic PVL No
Core valve 31 
mm
77 y, M 448 Stafylococcus 
aureus
2 Major + 4 
minor
Dead d Aortic valve 
vegetation
CRT-P, 1 year 
before TAVI
Core valve 31 
mm
80 y, M 528 Streptococcus 
oralis
1 Major + 1 
minor
Alive No vegetation or 
PVL
PM, 1 day after 
TAVI
Fig. 1  Individual changes in NYHA class from baseline (n = 82) to 6 
months (n = 78). The height of each bar is proportional to the number 
of patients with the corresponding NYHA class, and the width of the 
ends of each flow line is proportional to the number of patients with 
the given pattern of change of NYHA class
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We found a higher frequency of infective endocarditis 
(IE) than expected. In a recent meta-analysis with a mean 
follow-up at 3.4 years, the overall incidence of IE in TAVI 
was 2.0% [28]. In the present study, five of six patients with 
IE had a pacemaker or an ICD, which might be associated 
with an increased risk of IE [29]. Several single-centre stud-
ies finding higher incidences suggests that IE is underre-
ported in large studies and registries [30, 31]. Diagnosing 
endocarditis is challenging, and the presentation might be 
uncharacteristic since the patients are old with comorbidities 
[28]. As endocarditis can occur later on, longer follow-up 
than 1 year seems important. Antibiotic prophylaxis during 
the TAVI procedure were administered to all patients. Gen-
eral practitioners were informed routinely on discharge about 
the risk of endocarditis and indications for prophylaxis.
Prior to TAVI, patients need to be informed of expected 
NYHA class improvement, survival benefit and maintenance 
of activities of daily living. Rare and severe complications, 
like death, stroke and infectious endocarditis, should also 
be part of the pre- TAVI discussion with the patient. Old 
patients with substantial comorbidity need to be informed 
that TAVI will not solve all their health problems. After 
the study period, written information about the procedure 
and risks and benefits was developed and administered to 
patients as part of the decision-making process. Our findings 
may be used when developing and improving decision aids 
for this treatment in older adults.
Strengths of the study
All hospitals in Western Norway use the same electronic 
medical records and VARC-2 endpoints are complete with 
no patients lost to follow-up. All deaths are automatically 
registered in the patients’ electronic journal. The same 
investigator (ES) performed the assessment at baseline and 
6 months, increasing reliability.
Limitations of the study
This is a single centre study performed in the early era of 
TAVI and some of the results might not be transferable due 
to improvement of equipment, better patient selection and 
training of the interventional cardiologists performing the 
procedure. Most patients were independent before TAVI, and 
minor (nevertheless important to patients) improvements 
might not be revealed by the NEADL questionnaire. Due to 
the small sample size, it was not possible to analyse whether 
specific subgroups improved or deteriorated in NEADL. We 
performed only telephone interviews at 6 months, prevent-
ing us from assessing MMSE and frailty at follow-up. We 
assume that living in their own home 2 years after TAVI 
reflects independence of activities of daily living, however, 
we cannot exclude that some patients living at home were 
in need of extended care.
Conclusion
TAVI patients had symptom improvement and maintenance 
of activity of daily living at 6 months. They had low mortal-
ity, and most patients lived in their own home 2 years after 
TAVI. Severe complications, like death, stroke and endocar-
ditis, occurred. Balanced information regarding these risks 
and benefits is needed to ensure informed consent prior to 
the procedure, and our findings may be used to develop 
and improve decision aids assisting this process. Clinicians 
should be aware that some patients have cognitive impair-
ment before TAVI that might affect their power of judgement 
and decision-making.
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